• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

减少无菌药物剂量配制错误所带来的预计成本节约。

Estimated cost savings from reducing errors in the preparation of sterile doses of medications.

作者信息

Urbine Terry F, Schneider Philip J

机构信息

Associate Research Scientist and Instructor, Department of Pharmacy Practice and Science, University of Arizona College of Pharmacy , Phoenix, Arizona .

Professor and Associate Dean, Department of Pharmacy Practice and Science, University of Arizona College of Pharmacy , Phoenix, Arizona .

出版信息

Hosp Pharm. 2014 Sep;49(8):731-9. doi: 10.1310/hpj4908-731.

DOI:10.1310/hpj4908-731
PMID:25477598
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4252201/
Abstract

BACKGROUND

Preventing intravenous (IV) preparation errors will improve patient safety and reduce costs by an unknown amount.

OBJECTIVE

To estimate the financial benefit of robotic preparation of sterile medication doses compared to traditional manual preparation techniques.

METHODS

A probability pathway model based on published rates of errors in the preparation of sterile doses of medications was developed. Literature reports of adverse events were used to project the array of medical outcomes that might result from these errors. These parameters were used as inputs to a customized simulation model that generated a distribution of possible outcomes, their probability, and associated costs.

RESULTS

By varying the important parameters across ranges found in published studies, the simulation model produced a range of outcomes for all likely possibilities. Thus it provided a reliable projection of the errors avoided and the cost savings of an automated sterile preparation technology. The average of 1,000 simulations resulted in the prevention of 5,420 medication errors and associated savings of $288,350 per year. The simulation results can be narrowed to specific scenarios by fixing model parameters that are known and allowing the unknown parameters to range across values found in previously published studies.

CONCLUSIONS

The use of a robotic device can reduce health care costs by preventing errors that can cause adverse drug events.

摘要

背景

预防静脉注射(IV)配制错误将提高患者安全性并降低成本,具体降低幅度未知。

目的

评估与传统手工配制技术相比,使用机器人配制无菌药物剂量的经济效益。

方法

基于已发表的无菌药物剂量配制错误率建立概率路径模型。利用不良事件的文献报告来预测这些错误可能导致的一系列医疗后果。这些参数被用作定制模拟模型的输入,该模型生成可能结果的分布、其概率以及相关成本。

结果

通过在已发表研究中发现的范围内改变重要参数,模拟模型为所有可能情况生成了一系列结果。因此,它为避免的错误和自动化无菌配制技术的成本节约提供了可靠的预测。1000次模拟的平均值为每年预防5420次用药错误并节省288350美元。通过固定已知的模型参数并允许未知参数在先前发表的研究中发现的值范围内变化,模拟结果可以缩小到特定场景。

结论

使用机器人设备可通过预防可能导致药物不良事件的错误来降低医疗成本。

相似文献

1
Estimated cost savings from reducing errors in the preparation of sterile doses of medications.减少无菌药物剂量配制错误所带来的预计成本节约。
Hosp Pharm. 2014 Sep;49(8):731-9. doi: 10.1310/hpj4908-731.
2
3
Can Technology Assistance be Cost Effective in TKA? A Simulation-Based Analysis of a Risk-prioritized, Practice-specific Framework.技术辅助在全膝关节置换术(TKA)中是否具有成本效益?基于风险优先、特定实践的框架的模拟分析。
Clin Orthop Relat Res. 2023 Jan 1;481(1):157-173. doi: 10.1097/CORR.0000000000002375. Epub 2022 Sep 8.
4
[Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].[氯化乙酰甲胆碱支气管激发试验标准技术规范(2023年)]
Zhonghua Jie He He Hu Xi Za Zhi. 2024 Feb 12;47(2):101-119. doi: 10.3760/cma.j.cn112147-20231019-00247.
5
The Economic Impact of Smoking and of Reducing Smoking Prevalence: Review of Evidence.吸烟及降低吸烟率的经济影响:证据综述
Tob Use Insights. 2015 Jul 14;8:1-35. doi: 10.4137/TUI.S15628. eCollection 2015.
6
A Cost Minimization Analysis of Ready-to-Administer Prefilled Sterilized Syringes in a Dutch Hospital.一种用于荷兰医院的即用型预充式无菌注射器的成本最小化分析。
Clin Ther. 2019 Jun;41(6):1139-1150. doi: 10.1016/j.clinthera.2019.04.024. Epub 2019 May 10.
7
Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.多基因药物基因组学检测,包括用于指导抗抑郁药物选择的决策支持工具:一项卫生技术评估。
Ont Health Technol Assess Ser. 2021 Aug 12;21(13):1-214. eCollection 2021.
8
[Health technology assessment report: Computer-assisted Pap test for cervical cancer screening].[卫生技术评估报告:用于宫颈癌筛查的计算机辅助巴氏试验]
Epidemiol Prev. 2012 Sep-Oct;36(5 Suppl 3):e1-43.
9
Innovations in Medication Preparation Safety and Wastage Reduction: Use of a Workflow Management System in a Pediatric Hospital.药物配制安全与减少浪费方面的创新:儿科医院中工作流程管理系统的应用
Hosp Pharm. 2017 Jan;52(1):54-59. doi: 10.1310/hpj5201-54.
10
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.

引用本文的文献

1
Intravenous compounding robots in pharmacy intravenous admixture services: A systematic review.药学静脉药物配置服务中的静脉配置机器人:系统评价。
Medicine (Baltimore). 2023 May 12;102(19):e33476. doi: 10.1097/MD.0000000000033476.

本文引用的文献

1
Cost-effectiveness of asthma clinic approach in the management of chronic asthma in Australia.澳大利亚慢性哮喘管理中哮喘门诊方法的成本效益。
Aust N Z J Public Health. 2013 Jun;37(3):205-10. doi: 10.1111/1753-6405.12060.
2
Impact of robotic antineoplastic preparation on safety, workflow, and costs.机器人抗肿瘤制备对安全性、工作流程和成本的影响。
J Oncol Pract. 2012 Nov;8(6):344-9, 1 p following 349. doi: 10.1200/JOP.2012.000600. Epub 2012 Sep 25.
3
Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation.阿哌沙班、达比加群、利伐沙班和华法林预防房颤卒中的成本效益分析。
Stroke. 2013 Jun;44(6):1676-81. doi: 10.1161/STROKEAHA.111.000402. Epub 2013 Apr 2.
4
Intravenous chemotherapy preparation errors: patient safety risks identified in a pan-Canadian exploratory study.静脉化疗配制错误:一项全加拿大探索性研究中识别出的患者安全风险
J Oncol Pharm Pract. 2014 Feb;20(1):40-6. doi: 10.1177/1078155212473000. Epub 2013 Jan 24.
5
Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore.新加坡新诊断癫痫成年患者 HLA-B*1502 基因分型的成本效益分析。
Neurology. 2012 Sep 18;79(12):1259-67. doi: 10.1212/WNL.0b013e31826aac73. Epub 2012 Sep 5.
6
Errors during the preparation of drug infusions: a randomized controlled trial.药物输注准备过程中的错误:一项随机对照试验。
Br J Anaesth. 2012 Nov;109(5):729-34. doi: 10.1093/bja/aes257. Epub 2012 Jul 31.
7
Cost-effectiveness analysis of goal-directed hemodynamic treatment of elderly hip fracture patients: before clinical research starts.老年髋部骨折患者目标导向血流动力学治疗的成本效益分析:在临床研究开始之前。
Anesthesiology. 2012 Sep;117(3):519-30. doi: 10.1097/ALN.0b013e3182655eb2.
8
Cost-effectiveness analysis of 64-slice computed tomography vs. cardiac catheterization to rule out coronary artery disease before non-coronary cardiovascular surgery.64 层 CT 与心导管术用于非冠状动脉心血管手术前排除冠状动脉疾病的成本效益分析。
Eur Heart J Cardiovasc Imaging. 2013 Feb;14(2):149-57. doi: 10.1093/ehjci/jes121. Epub 2012 Jul 2.
9
Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.基于奥地利长期的流行病学数据,评估高危儿童呼吸道合胞病毒感染使用帕利珠单抗的成本效益。
Pediatr Infect Dis J. 2012 Jan;31(1):e1-8. doi: 10.1097/INF.0b013e318235455b.
10
Fondaparinux for isolated superficial vein thrombosis of the legs: a cost-effectiveness analysis.腿部孤立性浅表静脉血栓形成的磺达肝素钠:成本效益分析。
Chest. 2012 Feb;141(2):321-329. doi: 10.1378/chest.11-0625. Epub 2011 Jul 14.